CIK 0000886163 · Large accelerated filer
LIGAND PHARMACEUTICALS INC
Sign in to watch- Tickers
- LGND LGNDZ LGNXZ LGNYZ LGNZZ
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 770160744
- Phone
- 858-550-7500
- Business address
- 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO, CA, 92121
- Former names
- LIGAND PHARMACEUTICALS
Securities
- LGND Common Stock Nasdaq
- LGNDZ Common stock OTC
- LGNXZ Common stock OTC
- LGNYZ Common stock OTC
- LGNZZ Common stock OTC
- DEFA14A Proxy Proxy Materials
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 8-K Event Material agreement
- 4 Option exercise Director acquired 2,406 shares (option exercise)
- 4 Option exercise Director acquired 2,893 shares (option exercise)
- ARS Other Annual Report to Security Holders
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 8-K Event Bylaws or fiscal year change
- 4 Option exercise Chief Executive Officer acquired 16,015 shares (option exercise)
- 4 Open-market sale Director sold 1,893 shares at $74.30 ($140,650)
- 4 Option exercise Director acquired 2,893 shares (option exercise)
- 144 Insider Sale of Securities
- S-8 Other Securities Offered to Employees in Benefit Plans
- 4 Grant or award CHIEF LEGAL OFFICER & acquired 7,208 shares (grant or award)
- 4 Grant or award PRESIDENT & CHIEF OPERATING acquired 14,416 shares (grant or award)
- 4 Open-market sale Chief Financial Officer sold 140 shares at $88.46 ($12,384)
- 4 Grant or award CHIEF EXECUTIVE OFFICER acquired 32,436 shares (grant or award)
- 144/A Insider Sale of Securities
Page 14 of 115 · 2,300 filings